Achaogen Inc. (AKAO) is a late-stage company developing antibacterial medicines. The company’s lead product candidate is Plazomicin, designed to have a superior potency against Carbapenem-Resistant Enterobacteriaceae (CRE) infections.Plazomicin is under two phase III trials, dubbed EPIC and CARE, in patients with complicated urinary tract infections and patients with CRE infections, respectively.The top-line results from both the EPIC and CARE clinical trials are expected this month.AKAO is down nearly 11% so far this year, and trades around $5.11.